NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd
Post# of 122
(Total Views: 142)
Posted On: 12/06/2022 3:47:16 PM
NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has appointed a new scientific advisory board member: Dr. Matthias Dobbelstein, director of the Institute of Molecular Oncology at the University Medical Center Göttingen in Germany since 2005 and also an associate member of the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”). During his career, Dobbelstein has amassed impressive experience, particularly with his research, which has focused on principles of infections and cancer. He has studied the application of anticancer drugs as antivirals and has also worked with alpaca-derived NanoAbs, or nanosized antibodies known as nanobodies and VHH antibodies, as therapeutics. Dobbelstein and Dr. Dirk Görlich have provided research that serves as the scientific basis of BiondVax’s exclusive license for development and commercialization of an innovative, self-administered, inhaled NanoAb for the treatment of COVID-19, an approach that indicated significantly milder illness and faster recovery in a recent study. Dobbelstein and Görlich are collaborating with BiondVax to work toward the discovery, characterization and cloning of additional NanoAbs for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, asthma and macular degeneration. “We have been enjoying productive scientific cooperation with Professor Dobbelstein over the past year through our collaboration to develop his and Professor Görlich’s translational NanoAb research into a drug candidate for the treatment of COVID-19, which is currently being tested in a preclinical study,” said BiondVax Pharmaceuticals chief science officer Dr. Tamar Ben-Yedidia in the press release. “On behalf of BiondVax’s executive team, I am pleased to welcome Matthias to our SAB and am confident his deep scientific and clinical knowledge will meaningfully contribute to further building BiondVax into an innovative multi-asset pharmaceutical company.”
In addition, BiondVas announced that it has chosen InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, for its communications partner. According to the announcement, IBN will use its investor-based distribution network to generate greater awareness of the company; that network includes more than 5,000 syndication outlets as well as several newsletters, social media channels, wire services, blogs and other outreach tools. “BiondVax is guided by a highly experienced and successful pharmaceutical industry leadership team that includes former senior executives from Novartis, GSK and Bristol-Myers Squibb,” said IBN director of client solutions Chris Johnson in the press release. “We’re excited to customize our comprehensive suite of corporate communications solutions for the company as it moves toward a phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023. The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has appointed a new scientific advisory board member: Dr. Matthias Dobbelstein, director of the Institute of Molecular Oncology at the University Medical Center Göttingen in Germany since 2005 and also an associate member of the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”). During his career, Dobbelstein has amassed impressive experience, particularly with his research, which has focused on principles of infections and cancer. He has studied the application of anticancer drugs as antivirals and has also worked with alpaca-derived NanoAbs, or nanosized antibodies known as nanobodies and VHH antibodies, as therapeutics. Dobbelstein and Dr. Dirk Görlich have provided research that serves as the scientific basis of BiondVax’s exclusive license for development and commercialization of an innovative, self-administered, inhaled NanoAb for the treatment of COVID-19, an approach that indicated significantly milder illness and faster recovery in a recent study. Dobbelstein and Görlich are collaborating with BiondVax to work toward the discovery, characterization and cloning of additional NanoAbs for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, asthma and macular degeneration. “We have been enjoying productive scientific cooperation with Professor Dobbelstein over the past year through our collaboration to develop his and Professor Görlich’s translational NanoAb research into a drug candidate for the treatment of COVID-19, which is currently being tested in a preclinical study,” said BiondVax Pharmaceuticals chief science officer Dr. Tamar Ben-Yedidia in the press release. “On behalf of BiondVax’s executive team, I am pleased to welcome Matthias to our SAB and am confident his deep scientific and clinical knowledge will meaningfully contribute to further building BiondVax into an innovative multi-asset pharmaceutical company.”
In addition, BiondVas announced that it has chosen InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, for its communications partner. According to the announcement, IBN will use its investor-based distribution network to generate greater awareness of the company; that network includes more than 5,000 syndication outlets as well as several newsletters, social media channels, wire services, blogs and other outreach tools. “BiondVax is guided by a highly experienced and successful pharmaceutical industry leadership team that includes former senior executives from Novartis, GSK and Bristol-Myers Squibb,” said IBN director of client solutions Chris Johnson in the press release. “We’re excited to customize our comprehensive suite of corporate communications solutions for the company as it moves toward a phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023. The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)